{"title":"人单克隆抗体制备的研究进展","authors":"Shixia Wang","doi":"10.2147/ANTI.S20195","DOIUrl":null,"url":null,"abstract":"Correspondence: Shixia Wang, Associate Professor of Medicine, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA email shixia.wang@umassmed.edu Abstract: Since the development of hybridoma technology over three decades ago, numerous monoclonal antibodies have been produced and the use of monoclonal antibodies has become one of the major breakthroughs in medicine. Significant progress has been made on new technologies for generating human monoclonal antibodies. This review serves as an introduction to the immortalization of antigen-specific human B cell and hybridoma technologies, phage display platform, the use of transgenic mice, and the generation of monoclonal antibodies from single B cells.","PeriodicalId":50747,"journal":{"name":"Antibiotiques","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2011-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/ANTI.S20195","citationCount":"23","resultStr":"{\"title\":\"Advances in the production of human monoclonal antibodies\",\"authors\":\"Shixia Wang\",\"doi\":\"10.2147/ANTI.S20195\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Correspondence: Shixia Wang, Associate Professor of Medicine, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA email shixia.wang@umassmed.edu Abstract: Since the development of hybridoma technology over three decades ago, numerous monoclonal antibodies have been produced and the use of monoclonal antibodies has become one of the major breakthroughs in medicine. Significant progress has been made on new technologies for generating human monoclonal antibodies. This review serves as an introduction to the immortalization of antigen-specific human B cell and hybridoma technologies, phage display platform, the use of transgenic mice, and the generation of monoclonal antibodies from single B cells.\",\"PeriodicalId\":50747,\"journal\":{\"name\":\"Antibiotiques\",\"volume\":\"1 1\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/ANTI.S20195\",\"citationCount\":\"23\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antibiotiques\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/ANTI.S20195\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotiques","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/ANTI.S20195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23
摘要
通信:王世霞,马萨诸塞大学医学院医学系副教授,马萨诸塞州伍斯特市364 Plantation Street, MA 01605, USA email shixia.wang@umassmed.edu摘要:杂交瘤技术发展三十多年来,已经产生了大量的单克隆抗体,单克隆抗体的使用已成为医学的重大突破之一。制备人单克隆抗体的新技术取得了重大进展。本文综述了抗原特异性人B细胞和杂交瘤永生化技术、噬菌体展示平台、转基因小鼠的使用以及从单个B细胞中产生单克隆抗体的研究进展。
Advances in the production of human monoclonal antibodies
Correspondence: Shixia Wang, Associate Professor of Medicine, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA email shixia.wang@umassmed.edu Abstract: Since the development of hybridoma technology over three decades ago, numerous monoclonal antibodies have been produced and the use of monoclonal antibodies has become one of the major breakthroughs in medicine. Significant progress has been made on new technologies for generating human monoclonal antibodies. This review serves as an introduction to the immortalization of antigen-specific human B cell and hybridoma technologies, phage display platform, the use of transgenic mice, and the generation of monoclonal antibodies from single B cells.